Applied optics · 2025
Power distribution of collimated coherent radiation at 1061 nm over the corneal thickness.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Motylkova Elena V, Filatova Serafima A, Subbot Anastasia M, Kravchik Marina V, Kamynin Vladimir A, Osipyan Grigoriy A, Novikov Ivan A, Kuznetsov Sergey V, Yusef Yusef N
Аннотация
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant tumors, with approximately 80% of PDAC patients having locally advanced or metastatic disease at diagnosis. The liver is a predominant site of metastasis and is linked to a particularly poor prognosis. Here, we explored camrelizumab (an anti-programmed cell death-1 antibody) combined with albumin-bound paclitaxel and gemcitabine (AG) in patients with PDAC and liver metastases (PCLM).
METHODS: In this pilot trial (ChiCTR2000038587), patients received camrelizumab (200 mg on day 1) plus gemcitabine (1000 mg/m2 on days 1 and 8) and albumin-bound paclitaxel (125 mg/m2 on days 1 and 8) every 21-day cycle until disease progression, intolerable toxicity, or death. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety. Exploratory analyses evaluated potential biomarkers associated with survival.
RESULTS: From October 2018 to October 2023, 17 patients were enrolled. The median OS was 14.0 months (95% confidence interval [CI], 10.0-24.0) and the median PFS was 6.4 months (95% CI, 5.2-10.2). Five patients achieved an objective response (29.4%), with a DCR of 64.7%. Fewer liver metastasis lesions, higher white blood cell-to-lymphocyte ratio, and lower neutrophil-to-lymphocyte ratio were associated with improved PFS and OS (P<0.05). Grade 3 treatment-related adverse events (TRAEs) included platelet count decreased (2 [11.8%]) and neutrophil count decreased (1 [5.9%]). No grade 4 or 5 TRAEs occurred.
CONCLUSION: Camrelizumab combined with AG demonstrates promising antitumor activity in patients with PCLM, with an acceptable safety profile.
METHODS: In this pilot trial (ChiCTR2000038587), patients received camrelizumab (200 mg on day 1) plus gemcitabine (1000 mg/m2 on days 1 and 8) and albumin-bound paclitaxel (125 mg/m2 on days 1 and 8) every 21-day cycle until disease progression, intolerable toxicity, or death. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety. Exploratory analyses evaluated potential biomarkers associated with survival.
RESULTS: From October 2018 to October 2023, 17 patients were enrolled. The median OS was 14.0 months (95% confidence interval [CI], 10.0-24.0) and the median PFS was 6.4 months (95% CI, 5.2-10.2). Five patients achieved an objective response (29.4%), with a DCR of 64.7%. Fewer liver metastasis lesions, higher white blood cell-to-lymphocyte ratio, and lower neutrophil-to-lymphocyte ratio were associated with improved PFS and OS (P<0.05). Grade 3 treatment-related adverse events (TRAEs) included platelet count decreased (2 [11.8%]) and neutrophil count decreased (1 [5.9%]). No grade 4 or 5 TRAEs occurred.
CONCLUSION: Camrelizumab combined with AG demonstrates promising antitumor activity in patients with PCLM, with an acceptable safety profile.